Cancer & SURVIVEiT News
Category Filter:
FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma
FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of…
FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma
FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma On May 1, 2020, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (DARZALEX FASPRO, Janssen Biotech, Inc.) for adult patients with…
FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma
FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma On May 1, 2020, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (DARZALEX FASPRO, Janssen Biotech, Inc.) for adult patients with…
FDA approves isatuximab-irfc for multiple myeloma
FDA approves isatuximab-irfc for multiple myeloma On March 2, 2020, the Food and Drug Administration approved isatuximab-irfc(SARCLISA, sanofi-aventis U.S. LLC) in combination with pomalidomide and dexamethasone for adult patients with…
Life After Multiple Myeloma: A Survivor Story
Although considered relatively uncommon, the American Cancer Society predicts that just over 32,000 new cases of multiple myeloma will be diagnosed in 2020. It can be hard to detect early…
FDA approves daratumumab for multiple myeloma ineligible for autologous stem cell transplant
FDA approves daratumumab for multiple myeloma ineligible for autologous stem cell transplant On June 27, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with…